Latest Articles
Braces for fashion: E don turn trend for Nigeria? - BBC.com
Braces for fashion: E don turn trend for Nigeria? BBC.com
Published: June 29, 2024, 7 a.m.
The race to understand—and profit from—period blood - Mother Jones
The race to understand—and profit from—period blood Mother Jones
Published: June 26, 2024, 7 a.m.
Why Tayla Williams believes netball is the perfect place to spark a conversation about endometriosis and periods - ABC News
Why Tayla Williams believes netball is the perfect place to spark a conversation about endometriosis and periods ABC News
Published: June 24, 2024, 7 a.m.
The evolving roles of extracellular vesicles in embryo-maternal communication - Nature.com
The evolving roles of extracellular vesicles in embryo-maternal communication Nature.com
Published: June 21, 2024, 7 a.m.
Bindi Irwin’s Daughter Grace Is the Cutest ‘Adventure Buddy’ in a New Photo With Her Uncle Robert - SheKnows
Bindi Irwin’s Daughter Grace Is the Cutest ‘Adventure Buddy’ in a New Photo With Her Uncle Robert SheKnows
Published: June 21, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology
FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
This Tucson woman doesn’t trust the AZ GOP to protect access to contraceptives - The Copper Courier
This Tucson woman doesn’t trust the AZ GOP to protect access to contraceptives The Copper Courier
Published: June 18, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!